Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type 2 Diabetes Mellitus Patients in Colombia.

Lasalvia P, Baquero L, Otálora-Esteban M, Castañeda-Cardona C, Rosselli D

Value in health regional issues9 Jun 2017Cited by 10 (Europe PMC)

PMID29254540DOI10.1016/j.vhri.2016.10.006PepBankPUB-29254540

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Colombian T2DM model, total dulaglutide costs were US $8,633.
In plain wordsIn a Colombian diabetes computer model, dulaglutide costs totaled US $8,633.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableTotal modeled cost
Study
n: not applicable
Markov model of diabetic microvascular and macrovascular complications in Colombia
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Total costs related to dulaglutide, liraglutide, and glargine were US $8,633, US $10,756, and US $5,783, yielding 3.311 QALYs, 3.229 QALYs, and 3.156 QALYs, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A Markov model including diabetic microvascular and macrovascular complications was used to estimate cost-effectiveness. We used annual cycles, a 5-year time horizon, 5% discount rate, and third-party payer's perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2925454001
02Computer modelNot a test of Liraglutide aloneIn silicoOther
In a Colombian T2DM model, total liraglutide costs were US $10,756.
In plain wordsIn a Colombian diabetes computer model, liraglutide costs totaled US $10,756.
Peptide
Liraglutide
Outcome
Not applicableTotal modeled cost
Study
n: not applicable
Markov model of diabetic microvascular and macrovascular complications in Colombia
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Total costs related to dulaglutide, liraglutide, and glargine were US $8,633, US $10,756, and US $5,783, yielding 3.311 QALYs, 3.229 QALYs, and 3.156 QALYs, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A Markov model including diabetic microvascular and macrovascular complications was used to estimate cost-effectiveness. We used annual cycles, a 5-year time horizon, 5% discount rate, and third-party payer's perspective.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2925454002
03Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Colombian T2DM model, dulaglutide yielded 3.311 QALYs.
In plain wordsIn a Colombian diabetes computer model, dulaglutide yielded 3.311 quality-adjusted life-years.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableQuality-adjusted life-years
Study
n: not applicable
Markov model of diabetic microvascular and macrovascular complications in Colombia
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Total costs related to dulaglutide, liraglutide, and glargine were US $8,633, US $10,756, and US $5,783, yielding 3.311 QALYs, 3.229 QALYs, and 3.156 QALYs, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A Markov model including diabetic microvascular and macrovascular complications was used to estimate cost-effectiveness. We used annual cycles, a 5-year time horizon, 5% discount rate, and third-party payer's perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2925454003
04Computer modelNot a test of Liraglutide aloneIn silicoOther
In a Colombian T2DM model, liraglutide yielded 3.229 QALYs.
In plain wordsIn a Colombian diabetes computer model, liraglutide yielded 3.229 quality-adjusted life-years.
Peptide
Liraglutide
Outcome
Not applicableQuality-adjusted life-years
Study
n: not applicable
Markov model of diabetic microvascular and macrovascular complications in Colombia
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Total costs related to dulaglutide, liraglutide, and glargine were US $8,633, US $10,756, and US $5,783, yielding 3.311 QALYs, 3.229 QALYs, and 3.156 QALYs, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A Markov model including diabetic microvascular and macrovascular complications was used to estimate cost-effectiveness. We used annual cycles, a 5-year time horizon, 5% discount rate, and third-party payer's perspective.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2925454004
05Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Colombian T2DM model, dulaglutide dominated liraglutide through lower costs and higher QALYs.
In plain wordsIn a computer model, dulaglutide cost less and produced more quality-adjusted life-years than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableEconomic dominance
Study
n: not applicable
Markov model of diabetic microvascular and macrovascular complications in Colombia
Comparator
Liraglutide
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Dulaglutide dominated liraglutide given lower total costs and higher QALYs.
1 context sentence(design, population, supporting numbers)
Summary · context
A Markov model including diabetic microvascular and macrovascular complications was used to estimate cost-effectiveness. We used annual cycles, a 5-year time horizon, 5% discount rate, and third-party payer's perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2925454005
06Computer modelNot a test of Liraglutide aloneIn silicoOther
In a Colombian T2DM model, liraglutide had higher costs and fewer QALYs than dulaglutide.
In plain wordsIn a computer model, liraglutide cost more and produced fewer quality-adjusted life-years than dulaglutide.
Peptide
Liraglutide
Outcome
Not applicableEconomic dominance
Study
n: not applicable
Markov model of diabetic microvascular and macrovascular complications in Colombia
Comparator
Dulaglutide
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Dulaglutide dominated liraglutide given lower total costs and higher QALYs.
1 context sentence(design, population, supporting numbers)
Summary · context
A Markov model including diabetic microvascular and macrovascular complications was used to estimate cost-effectiveness. We used annual cycles, a 5-year time horizon, 5% discount rate, and third-party payer's perspective.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2925454006
07Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In a Colombian T2DM model, dulaglutide versus glargine had an ICER of US $18,385, exceeding the accepted threshold.
In plain wordsIn a computer model, dulaglutide exceeded the accepted cost-effectiveness threshold compared with glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableIncremental cost-effectiveness ratio
Study
n: not applicable
Markov model of diabetic microvascular and macrovascular complications in Colombia
Comparator
Glargine
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The estimated ICER for dulaglutide compared with glargine was US $18,385, greater than the accepted threshold.
1 context sentence(design, population, supporting numbers)
Summary · context
A Markov model including diabetic microvascular and macrovascular complications was used to estimate cost-effectiveness. We used annual cycles, a 5-year time horizon, 5% discount rate, and third-party payer's perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2925454007
08Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In the Colombian model, lower dulaglutide cost, greater glargine use, nondaily injection, and glucometry assumptions could lower ICERs below threshold.
In plain wordsIn the computer model, these changes could bring dulaglutide below the cost-effectiveness threshold compared with glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSensitivity of cost effectiveness
Study
n: not applicable
Markov model of diabetic microvascular and macrovascular complications in Colombia
Comparator
Glargine
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Sensibility analysis shows that decreased dulaglutide cost, increased consumption of glargine, nondaily injection, and number and cost of glucometry could result in ICERs lower than the threshold.
1 context sentence(design, population, supporting numbers)
Summary · context
A Markov model including diabetic microvascular and macrovascular complications was used to estimate cost-effectiveness. We used annual cycles, a 5-year time horizon, 5% discount rate, and third-party payer's perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2925454008
09Computer modelNot a test of Dulaglutide (Trulicity) aloneIn silicoOther
In the Colombian T2DM model, probabilistic sensitivity analysis gave consistent results for the dulaglutide comparisons.
In plain wordsIn the computer model, analysis of uncertainty gave consistent results for dulaglutide comparisons.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableProbabilistic sensitivity analysis
Study
n: not applicable
Markov model of diabetic microvascular and macrovascular complications in Colombia
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Probabilistic sensitivity analysis showed consistent results.
1 context sentence(design, population, supporting numbers)
Summary · context
A Markov model including diabetic microvascular and macrovascular complications was used to estimate cost-effectiveness. We used annual cycles, a 5-year time horizon, 5% discount rate, and third-party payer's perspective.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2925454009
10Computer modelNot a test of Liraglutide aloneIn silicoOther
In the Colombian T2DM model including liraglutide, probabilistic sensitivity analysis gave consistent results.
In plain wordsIn the computer model including liraglutide, analysis of uncertainty gave consistent results.
Peptide
Liraglutide
Outcome
Not applicableProbabilistic sensitivity analysis
Study
n: not applicable
Markov model of diabetic microvascular and macrovascular complications in Colombia
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Probabilistic sensitivity analysis showed consistent results.
1 context sentence(design, population, supporting numbers)
Summary · context
A Markov model including diabetic microvascular and macrovascular complications was used to estimate cost-effectiveness. We used annual cycles, a 5-year time horizon, 5% discount rate, and third-party payer's perspective.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2925454010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.